This article was originally published in The Gray Sheet
Executive SummaryDivestiture of non-occlusive arterial pump line to Baxter settles Federal Trade Commission antitrust charges in connection with the company's $106 mil. acquisition of Avecor on March 8, FTC announces March 10. Avecor's perfusion device, which is currently in the early stages of gaining market acceptance, offers consumers advantages over Medtronic's Bio-Pump, FTC notes
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.